Leen van Garsse

Leen van Garsse

Auto-generated profile, based on publicly available information

Leen van Garsse

Department of Cardiothoracic Surgery, Radboud University Medical Center , Nijmegen

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
PHPatrick Houthuizen
Patrick Houthuizen
LGLeen A.F.M. Van Garsse
Leen A.F.M. Van Garsse
TPThomas T. Poels
Thomas T. Poels
PJPeter de Jaegere
Peter de Jaegere
RBRobert M.A. van der Boon
Robert M.A. van der Boon
FPFrits W. Prinzen
Frits W. Prinzen
Background—: Transcatheter aortic valve implantation (TAVI) is a novel therapy for treatment of severe aortic stenosis. Although 30% to 50% of patients develop new left bundle-branch block (LBBB), its effect on clinical outcome is unclear. Methods and Results—: Data were collected in a multicenter registry encompassing TAVI patients from 2005 until 2010. The all-cause mortality rate at follow-up was compared between patients who did and did not develop new LBBB. Of 679 patients analyzed, 387 (57.0%) underwent TAVI with the Medtronic CoreValve System and 292 (43.0%) with the Edwards SAPIEN valve. A total of 233 patients (34.3%) developed new LBBB. Median follow-up was 449.5 (interquartile range, 174–834) days in patients with and 450 (interquartile range, 253–725) days in patients without LBBB ( P =0.90). All-cause mortality was 37.8% (n=88) in patients with LBBB and 24.0% (n=107) in patients without LBBB ( P =0.002). By multivariate regression analysis, independent predictors of all-cause mortality were TAVI-induced LBBB (hazard ratio [HR], 1.54; confidence interval [CI], 1.12–2.10), chronic obstructive lung disease (HR, 1.56; CI, 1.15–2.10), female sex (HR, 1.39; CI, 1.04–1.85), left ventricular ejection fraction ≤50% (HR, 1.38; CI, 1.02–1.86), and baseline creatinine (HR, 1.32; CI, 1.19–1.43). LBBB was more frequent after implantation of the Medtronic CoreValve System than after Edwards SAPIEN implantation (51.1% and 12.0%, respectively; P <0.001), but device type did not influence the mortality risk of TAVI-induced LBBB. Conclusions—: All-cause mortality after TAVI is higher in patients who develop LBBB than in patients who do not. TAVI-induced LBBB is an independent predictor of mortality.

1 October 2012 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
RNRutger-Jan Nuis
Rutger-Jan Nuis
JRJosep Rodés-Cabau
Josep Rodés-Cabau
JSJan-Malte Sinning
Jan-Malte Sinning
LGLeen van Garsse
Leen van Garsse
JKJoelle Kefer
Joelle Kefer
PJPeter P. de Jaegere
Peter P. de Jaegere
Background—Blood transfusion is associated with acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI). We sought to elucidate in more detail the relation between blood transfusion and AKI and its effects on short- and long-term mortality. Methods and Results—Nine hundred ninety-five patients with aortic stenosis underwent TAVI with the Medtronic CoreValve or the Edwards Valve in 7 centers. AKI was defined by the Valve Academic Research Consortium (absolute increase in serum creatinine ≥0.3 mg/dL [≥26.4 μmol/L] or ≥50% increase ≤72 hours). Logistic and Cox regression was used for predictor and survival analysis. AKI occurred in 20.7% (n=206). The number of units of blood transfusion ≤24 hours was the strongest predictor of AKI (≥5 units, OR, 4.81 [1.45–15.95], 3–4 units, OR, 3.05 [1.24–7.53], 1–2 units, OR, 1.47 [0.98–2.22]) followed by peripheral vascular disease (OR, 1.48 [1.05–2.10]), history of heart failure (OR, 1.43 [1.01–2.03]), leucocyte count ≤72 hours after TAVI (OR, 1.05 [1.02–1.09]) and European System for Cardiac Operative Risk Evaluation (EuroSCORE; OR, 1.02 [1.00–1.03]). Potential triggers of blood transfusion such as baseline anemia, bleeding-vascular complications, and perioperative blood loss were not identified as predictors. AKI and life-threatening bleeding were independent predictors of 30-day mortality (OR, 3.15 [1.56–6.38], OR, 6.65 [2.28–19.44], respectively), whereas transfusion (≥3 units), baseline anemia, and AKI predicted mortality beyond 30 days. Conclusions—AKI occurred in 21% of the patients after TAVI. The number of blood transfusions but not the indication of transfusion predicted AKI. AKI was a predictor of both short- and long-term mortality, whereas blood transfusion predicted long-term mortality. These findings indicate that outcome of TAVI may be improved by more restrictive use of blood transfusions.

1 February 2014 in EuroIntervention
Verified
Journal Article
Closed access
PHPatrick Houthuizen
Patrick Houthuizen
RBRobert M.A. van der Boon
Robert M.A. van der Boon
MUM. Urena
M. Urena
NMN. Van Mieghem
N. Van Mieghem
GBGuus B.R. Brueren
Guus B.R. Brueren
PJPeter de Jaegere
Peter de Jaegere
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 December 2013 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
RNRutger-Jan Nuis
Rutger-Jan Nuis
JSJan-Malte Sinning
Jan-Malte Sinning
JRJosep Rodés-Cabau
Josep Rodés-Cabau
MGMichael Gotzmann
Michael Gotzmann
LGLeen van Garsse
Leen van Garsse
PJPeter P. de Jaegere
Peter P. de Jaegere
Background—: There is scant information on the prevalence and factors associated with preoperative anemia in patients undergoing transcatheter aortic valve implantation (TAVI) and whether it is associated with mortality. We sought to determine the prevalence and factors associated with preoperative anemia in addition to the prognostic effects of the various levels of preoperative hemoglobin level on mortality in patients undergoing TAVI. Methods and Results—: Ten-center observational study encompassing 1696 patients with aortic stenosis who underwent TAVI was conducted. Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dL in women and <13.0 g/dL in men). The prevalence of preoperative anemia was 57%. Patient-related factors associated with preoperative anemia were (descending order of odds ratio [95% confidence interval]) as follows: anemia-related medication (4.90 [3.08–7.80]), history of heart failure (1.77 [1.43–2.20]), male sex (1.69 [1.32–2.16]), mitral regurgitation grade ≥III (1.61 [1.15–2.25]), history of malignancy (1.44 [1.03–2.09]), and peripheral vascular disease (1.33 [1.04–1.70]). The creatinine clearance was inversely associated with preoperative anemia (odds ratio, 0.92 [0.87–0.97]). In multivariable analyses, preoperative anemia was not associated with 30-day mortality (1.72 [0.96–3.12]; P =0.073) but showed the strongest association with 1-year mortality with a hazard ratio (95% confidence interval) of 2.78 (1.60–4.82) in patients with hemoglobin 50% of patients undergoing TAVI. Various baseline factors were related to anemia, which in turn was associated with 1-year mortality. Patients with anemia received more transfusions but mostly for indications unrelated to overt bleeding, whereas transfusion was independently associated with both early and 1-year mortality. These findings indicate that optimization of baseline factors related to preoperative anemia, in addition to more strict criteria of the use of blood products, may improve outcome after TAVI.

31 December 2004 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
BMBart Meyns
Bart Meyns
LGLeen Van Garsse
Leen Van Garsse
DBDerize Boshoff
Derize Boshoff
BEBenedicte Eyskens
Benedicte Eyskens
LMLuc Mertens
Luc Mertens
WDWillem Daenen
Willem Daenen

8 February 2011 in Circulation
Verified
Journal Article
Closed access
LGLeen A.F.M. Van Garsse
Leen A.F.M. Van Garsse
RBRachel M.A. ter Bekke
Rachel M.A. ter Bekke
VOVincent G.V.A. van Ommen
Vincent G.V.A. van Ommen